Emergent Biosolutions Stock Fundamentals
| EBS Stock | USD 5.71 0.20 3.63% |
Emergent Biosolutions fundamentals help investors to digest information that contributes to Emergent Biosolutions' financial success or failures. It also enables traders to predict the movement of Emergent Stock. The fundamental analysis module provides a way to measure Emergent Biosolutions' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emergent Biosolutions stock.
At this time, Emergent Biosolutions' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 74.5 M in 2025, whereas Other Operating Expenses is likely to drop slightly above 627.4 M in 2025. Emergent | Select Account or Indicator |
Emergent Biosolutions Company Operating Margin Analysis
Emergent Biosolutions' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Emergent Biosolutions Operating Margin | 0.25 % |
Most of Emergent Biosolutions' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Emergent Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Emergent Biosolutions has an Operating Margin of 0.2451%. This is 100.7% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 104.45% lower than that of the firm.
Emergent Biosolutions Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Emergent Biosolutions's current stock value. Our valuation model uses many indicators to compare Emergent Biosolutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emergent Biosolutions competition to find correlations between indicators driving Emergent Biosolutions's intrinsic value. More Info.Emergent Biosolutions is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Emergent Biosolutions' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Emergent Biosolutions by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Emergent Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emergent Biosolutions' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics of similar companies.Emergent Biosolutions is currently under evaluation in operating margin category among its peers.
Emergent Biosolutions ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Emergent Biosolutions' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Emergent Biosolutions' managers, analysts, and investors.Environmental | Governance | Social |
Emergent Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 898.37 M | ||||
| Shares Outstanding | 54.18 M | ||||
| Shares Owned By Insiders | 2.15 % | ||||
| Shares Owned By Institutions | 57.78 % | ||||
| Number Of Shares Shorted | 6.95 M | ||||
| Price To Earning | 1.67 X | ||||
| Price To Book | 0.69 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 1.01 B | ||||
| Gross Profit | 290.1 M | ||||
| EBITDA | 36.9 M | ||||
| Net Income | (190.6 M) | ||||
| Cash And Equivalents | 642.6 M | ||||
| Cash Per Share | 7.28 X | ||||
| Total Debt | 663.7 M | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 3.92 X | ||||
| Book Value Per Share | 9.40 X | ||||
| Cash Flow From Operations | 58.7 M | ||||
| Short Ratio | 5.21 X | ||||
| Earnings Per Share | (11.22) X | ||||
| Price To Earnings To Growth | 1.55 X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 900 | ||||
| Beta | 1.57 | ||||
| Market Capitalization | 540.22 M | ||||
| Total Asset | 1.39 B | ||||
| Retained Earnings | (212.4 M) | ||||
| Working Capital | 436.3 M | ||||
| Current Asset | 537.41 M | ||||
| Current Liabilities | 99.61 M | ||||
| Net Asset | 1.39 B |
About Emergent Biosolutions Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 30.4 M | 28.1 M | |
| Total Revenue | 1 B | 583.9 M | |
| Cost Of Revenue | 1.00 | 0.95 | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 0.30 | 0.31 | |
| Research And Ddevelopement To Revenue | 0.07 | 0.07 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 19.12 | 9.78 | |
| Ebit Per Revenue | (0.11) | (0.10) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.